Bank Julius Baer & Co
PRTK

Bank Julius Baer & Co’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Bank Julius Baer & Co’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,026
Closed -$7K – 878
2021
Q2 		$7K Buy
1,026
+26
+3% +$210 ﹤0.01% 796
2021
Q1 		$7K Buy
+1,000
New +$7.2K ﹤0.01% 791

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank Julius Baer & Co's PRTK Position: Q3 2021 in Review

Bank Julius Baer & Co sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 1,026 shares — an estimated $7K sold.

Bank Julius Baer & Co first reported a position in PRTK in Q1 2021 and held it in 2 quarters. The position peaked at $7K in Q2 2021. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • Bank Julius Baer & Co reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 1,026 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $7K.
  • Bank Julius Baer & Co first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2021 and held it in 2 quarters.
  • Bank Julius Baer & Co's Paratek Pharmaceuticals, Inc. position peaked at $7K in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on Bank Julius Baer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.